Medication Assisted Treatment Initiative (MATI)
The Division of Mental Health and Addiction Services (DMHAS) administers a system of care that consistently offers clients the means to seek and sustain recovery.
The DMHAS promotes evidence-based practices that include Medication-Assisted Treatment Initiative (MATI) in the management of substance use disorders. The U.S. Department of Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA) defines MATI as the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. MATI is clinically driven with a focus on individualized patient care. Research continues to demonstrate medication, along with behavioral therapies, results in successful outcomes.
The FDA has approved certain medications for the treatment of substance use disorders. For alcohol use disorder, the medications include: Naltrexone, Disulfiram and Acamprosate Calcium. The current medications approved for the treatment of opioid use disorders are: Methadone, Buprenorphine and Naltrexone. Click here for more information on these medications.
The DMHAS licenses numerous treatment programs that serve consumers that want more information or are interested in accessing MATI for their treatment. Licensed treatment programs are listed on this site at https://njsams.rutgers.edu/treatmentdirectory/. For information regarding treatment programs call the IME Addictions Access Center at 1-844-276-2777
Back to Specialty Treatment Programs
